who is eligible for glp 1 Qualifies Tirzepatide Medical Weight Loss Treatment? Can I Use My HSA

Patented: see www.takeda.com/en-us/patents Revised: 10/2025 PRINCIPAL DISPLAY PANEL - Kit Carton - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4622-01 Single-dose only For Intravenous Administration After Reconstitution Only Lyophilized powder for reconstitution ADYNOVATE and diluent preassembled in BAXJECT III system Rx Only Actual potency Takeda PRINCIPAL DISPLAY PANEL - Barrel Label - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Directions for use: see package insert Rx Only IU: LOT: EXP: Takeda 6521221 PRINCIPAL DISPLAY PANEL - Blister Label - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4622-02 Single-dose only 6521479 For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Do not open until time of use Do not use if packaging is opened or damaged Discard unused portion

Constipation and digestive changes Both tirzepatide and semaglutide slow gastric emptying, but they do so through somewhat different mechanisms

Patients should seek immediate medical attention if they experience severe, persistent abdominal pain, particularly if radiating to the back, accompanied by nausea and vomiting

Body composition changes are also more predictive of health outcomes than weight alone